The Role of Tenascin-C in Hypertrophic Scar Formation: Insights from Cell and Animal Experiments

References

• Luo QF. The combined application of bleomycin and triamcinolone for the treatment of keloids and hypertrophic scars: an effective therapy for treating refractory keloids and hypertrophic scars. Skin Res Technol. 2023;29(6):e13389. doi:10.1111/srt.13389
   PubMed Web of Science ®Google Scholar
• Sidgwick GP, Bayat A. Extracellular matrix molecules implicated in hypertrophic and keloid scarring. J Eur Acad Dermatol. 2012;26(2):141–152. doi:10.1111/j.1468-3083.2011.04200.x
   Web of Science ®Google Scholar
• Eremenko E, Ding J, Kwan P, Tredget EE. The biology of extracellular matrix proteins in hypertrophic scarring. Adv Wound Care. 2022;11(5):234–254. doi:10.1089/wound.2020.1257
   Web of Science ®Google Scholar
• Yang F, Chen E, Yang Y, et al. The Akt/FoxO/p27Kip1 axis contributes to the anti-proliferation of pentoxifylline in hypertrophic scars. J Cell Mol Med. 2019;23(9):6164–6172. doi:10.1111/jcmm.14498
   PubMed Web of Science ®Google Scholar
• Ji X, Tang Z, Shuai W, et al. Endogenous peptide LYENRL prevents the activation of hypertrophic scar-derived fibroblasts by inhibiting the TGF-β1/smad pathway. Life Sci. 2019;231:116674. doi:10.1016/j.lfs.2019.116674
   PubMed Web of Science ®Google Scholar
• Dabiri G, Tumbarello DA, Turner CE, Van de Water L. Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-beta1 autocrine loop. J Invest Dermatol. 2008;128(10):2518–2525. doi:10.1038/jid.2008.90
   PubMed Web of Science ®Google Scholar
• Liu B, Liu Y, Wang L, Hou C, An M. RNA-seq-based analysis of the hypertrophic scarring with and without pressure therapy in a bama minipig model. Sci Rep. 2018;8(1):11831. doi:10.1038/s41598-018-29840-6
   PubMedGoogle Scholar
• Raktoe RS, Rietveld MH, Out-Luiting JJ, et al. Exon skipping of TGFβRI affects signalling and ECM expression in hypertrophic scar-derived fibroblasts. Scars Burn Heal. 2020;6:2059513120908857. doi:10.1177/2059513120908857
   Google Scholar
• Bi S, Cao C, Chai LL, Li SR, Yang DY. Regulatory mechanism of miR-29 over TGF-β1 and COL1 in scar cells. Eur Rev Med Pharmaco. 2017;21(10):2512–2517.
   PubMed Web of Science ®Google Scholar
• Zhou R, Zhang Q, Zhang Y, Fu S, Wang C. Aberrant miR-21 and miR-200b expression and its pro-fibrotic potential in hypertrophic scars. Exp Cell Res. 2015;339(2):360–366. doi:10.1016/j.yexcr.2015.10.018
   PubMed Web of Science ®Google Scholar
• Ming X, Qiu S, Liu X, et al. Prognostic role of Tenascin-c for cancer outcome: a meta-analysis. Technol Cancer Res T. 2019;18:1533033818821106.
   Web of Science ®Google Scholar
• Spenlé C, Saupe F, Midwood K, Burckel H, Noel G, Orend G. Tenascin-C: exploitation and collateral damage in cancer management. Cell Adhes Migr. 2015;9(1–2):141–153. doi:10.1080/19336918.2014.1000074
   PubMed Web of Science ®Google Scholar
• Rupp T, Langlois B, Koczorowska MM, et al. Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro- and anti-angiogenic signaling. Cell Rep. 2016;17(10):2607–2619. doi:10.1016/j.celrep.2016.11.012
   PubMed Web of Science ®Google Scholar
• Ogawa K, Ito M, Takeuchi K, et al. Tenascin-C is upregulated in the skin lesions of patients with atopic dermatitis. J Dermatol Sci. 2005;40(1):35–41. doi:10.1016/j.jdermsci.2005.06.001
   PubMed Web of Science ®Google Scholar
• Han CM, He XJ, Ma Q. 瘢痕疙瘩和增生性瘢痕中生腱蛋白-C mRNA的表达 [The expression of Tenascin-C mRNA in keloids and hypertrophic scars]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2005;21(1):40–43. Chinese.
   PubMedGoogle Scholar
• Indumathi A, Senthilkumar GP, Jayashree K, Ramesh Babu K. Assessment of circulating fibrotic proteins (periostin and Tenascin -C) in type 2 diabetes mellitus patients with and without retinopathy. Endocrine. 2022;76(3):570–577. doi:10.1007/s12020-022-03027-6
   PubMed Web of Science ®Google Scholar
• Yang JH, Yoon JY, Moon J, Min S, Kwon HH, Suh DH. Expression of inflammatory and fibrogenetic markers in acne hypertrophic scar formation: focusing on role of TGF-β and IGF-1R. Arch Dermatol Res. 2018;310(8):665–673. doi:10.1007/s00403-018-1856-2
   PubMed Web of Science ®Google Scholar
• Lian N, Li T. Growth factor pathways in hypertrophic scars: molecular pathogenesis and therapeutic implications. Biomed Pharmacother. 2016;84:42–50. doi:10.1016/j.biopha.2016.09.010
   PubMed Web of Science ®Google Scholar
• Oliveira GV, Alvarenga LRMG, Ramos-e-Silva M. Keloids and hypertrophic scars. Skinmed. 2022;20(6):432–443.
   PubMedGoogle Scholar
• Salem SAM, Abdel Hameed SM, Mostafa AE. Intense pulsed light versus cryotherapy in the treatment of hypertrophic scars: a clinical and histopathological study. J Cosmet Dermatol. 2021;20(9):2775–2784. doi:10.1111/jocd.13971
   PubMed Web of Science ®Google Scholar
• Tawfic SO, Hassan AS, El‐Zahraa SH Aly F, Elbendary A, Shaker OG, AlOrbani AM. Fractional microneedle radiofrequency versus fractional carbon dioxide laser in the treatment of postburn hypertrophic scars. Laser Surg Med. 2022;54(8):1089–1098. doi:10.1002/lsm.23589
   PubMed Web of Science ®Google Scholar
• Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci. 2018;19(3):711.
   PubMed Web of Science ®Google Scholar
• Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol. 2002;197(3):388–394. doi:10.1002/path.1131
   PubMed Web of Science ®Google Scholar
• Hagiwara K, Harimoto N, Yokobori T, et al. High co-expression of large Tenascin C splice variants in stromal tissue and annexin a2 in cancer cell membranes is associated with poor prognosis in pancreatic cancer. Ann Surg Oncol. 2020;27(3):924–930. doi:10.1245/s10434-019-07708-x
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang G, Liu H. Tenascin-C: a key regulator in angiogenesis during wound healing. Biomolecules. 2022;12(11):1689. doi:10.3390/biom12111689
   PubMed Web of Science ®Google Scholar
• Sylakowski K, Hwang P, Justin A, et al. Matricellular protein Tenascin-C enhances mesenchymal stem cell angiogenic and wound healing efficacy under ischemic conditions. J Tissue Eng Regen M. 2022;16(12):1249–1260. doi:10.1002/term.3367
   PubMed Web of Science ®Google Scholar
• Estany S, Vicens-Zygmunt V, Llatjós R, et al. Lung fibrotic Tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1. BMC Pulm Med. 2014;14(1):120. doi:10.1186/1471-2466-14-120
   PubMedGoogle Scholar
• Pang X, Hou X, Hu C, et al. Tenascin-C promotes the proliferation and fibrosis of mesangial cells in diabetic nephropathy through the β-catenin pathway. Int Urol Nephrol. 2023;55(10):2507–2516. doi:10.1007/s11255-023-03547-8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu Y, Chen Y, et al. Transdermal delivery of 5-aminolevulinic acid by nanoethosome gels for photodynamic therapy of hypertrophic scars. Acs Appl Mater Inter. 2019;11(4):3704–3714. doi:10.1021/acsami.8b17498
   PubMed Web of Science ®Google Scholar
• Dai Z, Lou X, Shen T, et al. Combination of ablative fractional carbon dioxide laser and platelet-rich plasma treatment to improve hypertrophic scars: a retrospective clinical observational study. Burns Trauma. 2021;9:tkab016. doi:10.1093/burnst/tkab016
   PubMed Web of Science ®Google Scholar
• de Oliveira GV, Gold MH. Hydrocolloid dressings can be used to treat hypertrophic scars: an outpatient dermatology service devoted to treat keloids and challenging scars. J Cosmet Dermatol. 2020;19(12):3344–3348. doi:10.1111/jocd.13792
   PubMed Web of Science ®Google Scholar